Liver damage arrests growth mediated by the somatotroph axis, which prevents liver cell death and inflammation, but increases fibrosis in nonalcoholic fatty liver disease (NAFLD). The explanation for this effect could lie in the relationship between the activating transcription factor 3 (ATF-3) and insulin-like growth factor 1 (IGF-1), according to a study from the University of California at Berkeley.

Starton Therapeutics Inc. has reported findings from a preclinical efficacy study of STAR-LLD, a continuous delivery system of lenalidomide, in a lenalidomide-resistant animal model. The 28-day efficacy study evaluated STAR-LLD continuous subcutaneous (s.c.) infusion versus intraperitoneal (i.p.) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice.

1st Biotherapeutics Inc. has received clearance from the FDA for its IND application to evaluate FB-849, a small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumors.

Severe toxicities associated with immune checkpoint inhibitor (ICI) therapy are a major challenge of this anticancer therapy approach. While myocarditis is a rare immune-related adverse event in patients receiving ICIs, it has a nearly 50% mortality rate and its pathogenesis is poorly understood. In the current study, researchers from Vanderbilt University and affiliated organizations published data from a study that evaluated a novel mouse model recapitulating clinical and pathological features of ICI-associated myocarditis (ICI-MC).